Skip to main content
Download PDF
Download ePub
  • Study protocol
  • Open access
  • Published:

Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)—study protocol for a 2×2 factorial randomized trial

Implementation Science volume 11, Article number: 131 (2015) Cite this article

Abstract

Background

Chronic diseases result in significant morbidity and costs. Although medications and lifestyle changes are effective for improving outcomes in chronic diseases, many patients do not receive these treatments, in part because of financial barriers, patient and provider-level knowledge gaps, and low patient motivation. The Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS) will determine the impact of two interventions: (1) a value-based formulary which eliminates copayment for high-value preventive medications; and (2) a comprehensive self-management support program aimed at promoting health behavior change and medication adherence, combined with relay of information on medication use to healthcare providers, on cardiovascular events and/or mortality in low-income seniors with elevated cardiovascular risk.

Methods

The ACCESS study will use a parallel, open label, factorial randomized trial design, with blinded endpoint evaluation in 4714 participants who are over age >65 (and therefore have drug insurance provided by Alberta Blue Cross with 30 % co-payment); are at a high risk for cardiovascular events based on a history of any one of the following: coronary heart disease, prior stroke, chronic kidney disease, heart failure, or any two of the following: current cigarette smoking, diabetes mellitus, hypertension, or hypercholesterolemia; and have a household income <Can$50,000. This 3-year study is powered to detect a minimal clinically important relative risk reduction of 12 % in the composite clinical outcome of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, and hospitalizations for chronic disease-related ambulatory care sensitive conditions, each of which will be assessed using healthcare administrative data. Secondary outcomes will include quality of life and healthcare costs.

Discussion

Given identified gaps in care in chronic disease, and the frequency of financial and knowledge-related barriers in low-income Albertans, this study will test the impact of providing free high-value preventive medications (i.e., value-based insurance) and a tailored self-management education and facilitated relay strategy on outcomes and costs. By measuring the impact on both health outcomes and costs, as well as the impact on reducing health inequities in this vulnerable population, our study will facilitate informed policy decisions.

Trial registration

Clinicaltrials.gov: NCT02579655. Registered Oct 15, 2015.

Peer Review reports

Background

The World Health Organization estimates that nearly one third of worldwide deaths are from cardiovascular disease [1]. Approximately 80 % of these are from myocardial infarctions and strokes. Similar statistics have been demonstrated in Canada [2]. Important risk factors for cardiovascular events include prior stroke or myocardial infarction, chronic kidney disease, heart failure, diabetes, or hypertension (henceforth referred to as “chronic diseases”).

Health behavior changes (e.g., exercise, healthy diet, smoking cessation, and adherence with pharmacologic preventive management) are particularly important in the management of people with these chronic diseases [3–7]. We identified a significant evidence to care gap for people with chronic diseases in Alberta, Canada, similar to that observed in other North American populations, including that nearly 50 % of people with cardiovascular-related chronic diseases do not take guideline-recommended medications (e.g., statins) [8].

As occurs in nearly all organizations for economic co-operation and development countries [9], most Canadian citizens (irrespective of whether they have private or publicly funded drug insurance) are subject to cost-sharing (i.e., copayments or deductibles) [10]. This requires that patients pay a portion of the medication cost—typically a copayment of 20–30 % of the total cost of the prescription [11]—or deductibles which may be as high as 5–20 % of household income [12]. In a recent survey of nearly 2000 Western Canadians, up to 20 % of Western Canadian patients identified having financial barriers to obtaining their drugs; and patients with these barriers were 30–55 % less likely to use statins than those who did not perceive financial barriers [10].

In addition to financial barriers, in our recent survey of Western Canadians, we also identified that patient and provider-level knowledge gaps and patient motivation were major barriers to optimal medical management [13]. Patient knowledge and motivation both tie into the concept of self-management [14]: a set of positive health behaviors which include adherence to prescribed medications. Our recent survey suggested that 40 % of patients with these chronic conditions did not recall receiving health behavior change counseling, and of those who did, up to 70 % of them did not report following the advice given [13].

Management of chronic disease may be suboptimal when patients experience financial barriers or do not engage in self-management. If suboptimal control persists for extended periods, patients may be hospitalized for complications [15] such as myocardial infarction, stroke, coronary revascularization, or chronic disease-related ambulatory care sensitive conditions (ACSC). ACSC are those for which “timely and effective outpatient care, including use of appropriate medications, can reduce the risk of hospitalization” [16]. These potentially preventable hospitalizations are clinically relevant to patients and for health systems [17–19].

Rationale for study interventions

  1. a)

    Value-based formulary which eliminates copayment for high-value preventive medications

One way to reduce the frequency of financial barriers is to provide full coverage for “high-value” medications. Also known as value-based insurance, within a value-based formulary, medications shown to confer important benefits in high quality studies, and/or provide good value for money are provided for free, with other lower-value medications still subject to patient copayment [20]. Numerous observational studies have suggested that reducing copayments has the potential to improve adherence [20], and a recent high-quality randomized clinical trial (MI-FREEE) has demonstrated that eliminating copayments for beta-blockers, angiotensin converting enzyme inhibitors, statins, and antiplatelet agents in patients post-myocardial infarction reduced the total number of cardiovascular events [21]. The impact of value-based insurance in a broader patient population has not been tested using a rigorous study design. The ACCESS study is powered to determine the impact of value based insurance in a broader patient population on both clinical outcomes and costs—and as such will address an important gap in the literature.

  1. b)

    Self-management support program

A variety of interventions to enhance patient self-management have been tested in people with chronic diseases within randomized clinical trials [22]. Within a recent systematic review that sought to determine which elements of such programs were most effective in people with diabetes, interventions to enhance self-management, patient education, and facilitated relay of information to clinicians were noted to be some of the most effective interventions at improving glycemic control and blood pressure [22]. “Facilitated relay” is defined as clinical information transmitted to clinicians by means other than the existing medical record [22]; the expectation is that clinicians act on the information to improve patient management. The systematic review noted considerable heterogeneity in the observed efficacy of the self-management programs. Part of this difference may relate to the format of the message, which (when crafted and delivered by health care workers) may lack effective techniques demonstrated to promote behavior change, and may not be tailored appropriately to individuals’ preferences and values [23]. Additional uncertainty with respect to the effectiveness of interventions to enhance self-management, patient education, and facilitated relay of information to clinicians was also noted because of low sample sizes and short study duration (almost all studies <6 months) [22]. This uncertainty will be addressed by the ACCESS study, which will be powered to detect differences in clinical and cost outcomes.

Objectives

The Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS) will determine the effectiveness of two interventions targeting financial and self-management related barriers:

  1. (i)

    a value-based formulary that eliminates co-payment for select high-value medications (i.e., value based insurance); and

  2. (ii)

    a comprehensive self-management support program aimed at promoting health behavior change (by addressing concerns and improving self-efficacy), combined with relay of information on medication use to health care providers on cardiovascular events and/or mortality in low-income seniors with elevated cardiovascular risk.

Trial design

ACCESS is a pragmatic, parallel group, open-label, factorial randomized controlled trial with blinded endpoint evaluation of the two interventions described above. In this 2×2 design, there will be four treatment arms with an allocation ratio of 1:1:1:1. We will assess the impact of these interventions on both relevant clinical outcomes and healthcare system costs over a 3-year follow-up period.

Methods

Study setting

The ACCESS trial will recruit community-based participants living in Alberta, the fourth largest Canadian province with a population of 4.2 million [24]. In Canada, universal public health insurance provides physician and hospital services free of charge to all citizens and residents, but Alberta government-sponsored drug insurance is only provided without premium to people receiving social assistance and those over the age of 65 years. Those over age 65 pay 30 % copayment for drugs (to a maximum of $25 per prescription).

Eligibility criteria

Inclusion criteria include: (a) age greater than 65 years with Alberta government-sponsored seniors drug insurance (30 % copayment), (b) high cardiovascular risk based on a history of any one of: heart disease, stroke, chronic kidney disease, heart failure, or any two of: current smoking, diabetes, hypertension, or high cholesterol; and (c) household income <$50,000.

Exclusion criteria include: (a) coverage by a secondary insurance plan (in addition to Blue Cross), resulting in patient-borne copayment of <30 %, or (b) inability to participate in self-management modules due to cognitive impairment or a lack of an English-speaking family member or close friend.

Goals of interventions

The overarching purposes of the interventions in the ACCESS study will be to:

  1. (1)

    Increase initiation and adherence to medications that have been proven to reduce the risk of cardiovascular events in this population of high risk patients, including HMG-CoA reductase inhibitors (Statins) [25] and renin-angiotensin-aldosterone system inhibitors (ACE inhibitors [ACEi] and angiotensin receptor blockers [ARBs]) [26].

  2. (2)

    Encourage participants to make positive health behavior changes, including healthy dietary choices, engagement in physical activity, cessation of tobacco use, and increased adherence to all preventive medications.

Intervention 1 will be enrolment in a new drug formulary (operationalized through their existing government drug insurance) that will eliminate copayments for high value preventive medications (those which prevent myocardial infarction, strokes, hospitalizations and delay progression of kidney and other vascular disease): statins, beta blockers, ACE-i, ARBs, calcium channel blockers, diuretics, anti-platelet agents, anti-arrhythmic drugs, anticoagulants, oral anti-diabetes agents, insulins, and smoking cessation aids (Additional file 1: Appendix 1).

Intervention 2 will be a tailored, adaptive, and interactive self-management support system that attempts to address determinants of intention and self-efficacy with regards to improving health habits and medication taking behavior. The second component of this intervention is comprised of facilitated relay of participants’ current use of recommended medications to their regular healthcare providers to facilitate prescription changes as needed, with the goal of overcoming clinical inertia.

The system was designed by behavioral and implementation scientists, clinical experts, health services researchers, in partnership with a health marketing firm (Emergence, New York, NY) and a health technology firm (Locus Health, Charlottesville, VA) to incorporate principles of design-thinking and brand-engagement, informed by a process of patient engagement, as described below. Details, including the final design and implementation plan, are presented in the Box.

Control arms

The control arm for intervention 1 (copayment elimination) is the usual pharmaceutical insurance plan. Those who are randomized to usual insurance coverage continue to have access to their regularly prescribed medications through their Alberta Blue Cross seniors plan with their usual 30 % copayment to a maximum of $25 per prescription.

The control for intervention 2 (the self-management intervention) has access to generic chronic disease information. Participants in this study arm are provided with a link to a government website (myhealth.alberta.ca) housing health information on a variety of conditions written by the company Healthwise. Participants can find information that interests them on a self-directed basis. They are also automatically subscribed to receive the quarterly patient-focused magazine published by Alberta Health Services.

Outcomes

The primary outcome is the composite rate of all-cause mortality, MI, stroke, coronary revascularization (coronary artery bypass grafting, angioplasty, or coronary stenting), and hospitalizations for cardiovascular-related ambulatory care-sensitive conditions defined using validated algorithms through administrative data [16] (Additional file 1: Appendix 2). As an individual may experience multiple events, a rate outcome will be used rather than a binary composite. Secondary outcomes include: (1) individual components of the primary endpoint, (2) changes to medication adherence, medication self-efficacy and needs-concerns states (see below), and (3) overall quality of life. Alongside the clinical trial, we are also planning a cost-effectiveness analysis, and a qualitative descriptive study, both described briefly in separate sections below.

Sample size

We identified a cohort of 170,000 Alberta seniors from the Interdisciplinary Chronic Disease Collaboration (ICDC) Chronic Disease Repository (Additional file 1: Appendix 3) who would meet study entry criteria. We found that the annual composite primary outcome event rate was estimated as 14 per 100 participant years. We used this rate to determine sample size requirements [32], assuming a minimal clinically important relative risk reduction of 12, α = 5 %, 80 % power, allocation ratio of 1:1, average follow up of 3 years and presumed 1 percent per year loss to follow-up (due to outmigration from Alberta) [33]. Also, 4714 patients are required, assuming no important interaction between our two interventions, which was tested using simulations with plausible interactions of 25 and 50 %.

Recruitment strategies

Participants will be recruited via signage in primary care and specialist physician offices as well as in pharmacies. Several hundred pharmacies across the province have agreed to participate in recruitment for this trial by posting study posters and by handing recruitment brochures to any patients filling medications that would suggest they might be eligible for this study (anti-hypertensive or anti-diabetes medications). We will also recruit using local newspapers and community newsletters, through senior’s groups as well as mass media (television, radio and social media).

Sequence generation and allocation concealment

Once baseline surveys have been returned to the study team and we have verified eligibility, randomization to the interventions will occur in a 1:1:1:1 fashion via a computer generated randomization program.

A randomized treatment allocation table was created on October 28, 2015 using sealedenvelope.com. Four treatment groups were used (intervention 1 only, intervention 2 only, interventions 1 and 2, and no intervention/control). Variable block sizes were used and the list length was 7200. Randomization was stratified by age (<70 years, ≥70 years); income (< $30,000, ≥$30,000); and sex (Male, Female).

Study data will be collected and managed using REDCap electronic data capture tools hosted at the University of Calgary, in collaboration with the Cumming School of Medicine. The randomization module was enabled in REDCap, and the allocation table produced by Sealed Envelope was imported into the web-based application. Patients will be entered into the database and randomized, in a concealed fashion, according to this table by the study coordinating centre.

Blinding

Given the pragmatic nature of copayment elimination, blinding is not possible for this intervention. For the self-management intervention, even control patients will receive a basic version of potentially relevant educational materials, in essence being single-blinded for this part of the study.

However, to deal with the risk of ascertainment bias in this observational study, administrative data codes defining the primary and secondary outcomes were defined in advance (Additional file 1: Appendix 2) and outcome assessment will be blinded by having an analyst who does not have access to treatment information.

Data collection

Subjective outcomes such as quality of life, self-efficacy, and needs-concerns will be obtained from surveys administered at baseline, 6, 18, and 36 months (study completion). Objective outcomes will be assessed using the ICDC Chronic Disease Repository [32], which includes provincial laboratory and administrative health data (including vital statistics, pharmacy claims, physician claims, hospitalizations, emergency department and outpatient visits, and all health care costs) for all Albertans (Additional file 1: Appendix 3). This dataset has been used for many observational studies [34–37] and for assessing outcomes in a RCT of over 20,000 individuals [33].

Primary endpoint: the use of administrative databases to identify clinical conditions and outcomes has been validated in numerous high-quality studies [38–40], and the specific ICD-10 codes we have chosen to define the outcomes have been endorsed by respected national organizations [41] and based on validated algorithms applied to administrative health data [38, 40, 42–47].

Secondary endpoints:

  1. (1)

    Medication adherence: measured by the “number of days dispensed”/“number of days between prescription renewals” [48, 49] using drug data in the ICDC Chronic Disease Repository. Patients with medication supplies to cover ≥80 % of observed treatment days are considered adherent [21, 50].

  2. (2)

    Quality of life: we will administer the Euroqol EQ5D-5 L [51–53] at 6, 18, and 36 months [54]. The Canadian-specific EQ5D index score will be the primary quality of life measure [55].

  3. (3)

    Medication self-efficacy: we will administer the validated MASES questionnaire [56] at baseline and at study completion.

  4. (4)

    Necessity-concerns: we will administer the validated BMQ-specific questionnaire [57] at baseline and at study completion.

Data management

Data entry for paper surveys will be done using iDataFax (DF/Net Research Inc I, Seattle, WA) with duplicate verification. All data will be stored in the study’s central data repository on secured University of Calgary servers within the Clinical Research Unit. Given the low-risk nature of our interventions, and since our outcomes will be assessed using administrative data (with a one-year lag to receipt of data), there will be no external data safety and monitoring board. This study is considered low risk since patients’ physicians remain ultimately responsible for managing patients’ medical treatments and any complications that may arise as part of their treatment.

Statistical analysis

Primary outcome:

A Poisson model will test the main effects of the impact of the interventions on the rate of the primary outcome. This technique was chosen as individuals may experience multiple outcomes prior to the end of the study period, therefore we will account for both number of events and varying observation time within the Poisson model. The likelihood ratio test will test a negative binomial regression model within the Poisson model to examine for the presence of over dispersion. If present, negative binomial models will be used. The Vuong test will examine for excess zeros [58]. If present, zero-inflated models will be used.

Secondary outcomes:

Medication adherence is a binary variable and will be analyzed using log binomial regression (generalized linear models with a log link)—given the likely high prevalence of non-adherence. EQ5D index scores are continuous and will be analyzed using linear regression. Medication self-efficacy and concerns will be dichotomized and analyzed using logistic regression.

All analyses will be done using the “intention to treat” principle. Subgroup analyses will be based on underlying chronic disease and income status. Multiple imputations will be used to handle missing data.

Cost-effectiveness analysis

Alongside this randomized trial, we will conduct a cost-utility analysis using the EQ5D index scores collected within the trial and administrative data sources to obtain costing information.

Background

Using the cohort of 170,000 Albertans noted above, cost of health care (physician, hospitalization, ambulatory care, and drug costs) was noted to exceed $12,000 per patient-year, with ~35 % of these costs related to components of the primary outcome (Table 1). We will assess whether reductions in the overall costs of care offset the cost of copayment elimination, or enhanced self-management education.

Table 1 Healthcare costs over a three-year period for a cohort of 170,000 Albertans noted as potentially eligible for this study using administrative health data
Full size table

Objective

The objective is to determine the cost per quality adjusted life year gained for the two study interventions in low-income seniors with chronic diseases.

Methods

We will calculate the total costs of care for patients randomized to each of the interventions. Using administrative data, the cost of physician visits, emergency department visits, chronic disease-related hospitalizations, outpatient interventions related to chronic diseases and medications will be calculated for each participant. Alberta Health uses CIHI case mix grouper methods and ambulatory case costing methods to estimate hospital and outpatient costs, respectively. Physician claims will be based on the amount paid by Alberta Health [59, 60]. If needed, extrapolation over a patient’s lifetime will be made using decision analysis [59, 60].

Qualitative descriptive study

Overview

Qualitative research methods will be used to explore which intervention components did or did not work, why and in what contexts, by eliciting participants’ views and their reasons for non-adherence or adherence to self-management recommendations (including adherence to medications).

Sampling

A purposive sampling strategy will reflect: sex; type of chronic condition; income; and perception of a financial barrier. Five to ten participants will be selected from each of three active study arms (co-payment elimination only, self-management only, and both) across four groups of interest (those not on statins at baseline who started statins, those not on statins at baseline who remained off statins, those on statins at baseline with poor adherence but whose adherence improved, and those on statins at baseline with poor adherence and no improvement) resulting in a total of 12 groups. Sampling will continue to saturation, which we expect to occur at between 60-120 interviews.

Data collection

Telephone interviews will be conducted by a trained research assistant six months after enrolment to explore: general perceptions as to whether the intervention addressed individuals’ barriers; which aspects participants found helpful or not; why the intervention was successful at changing individual health behaviors or not; how the intervention affected individual’s quality of life (positively or negatively) and how the intervention could have been more impactful.

Data analysis

Qualitative descriptive/thematic analysis will be undertaken using qualitative data analysis and management software. Initial microcoding will break transcribed data into granular concepts, with subsequent coding to group concepts into themes. All analyses will be performed in duplicate by experienced qualitative data analysts.

Impact of qualitative study

In addition to gaining a better understanding of why the intervention(s) did or did not work, the results will be used to refine the self-management intervention that is provided in the remainder of the study, and will provide explanatory power for trial findings, especially if the interventions do not improve adherence and health outcomes.

Discussion

Given the frequency of financial barriers to medication use in low-income Albertans, this study will test the impact of a value-based formulary which eliminates copayment for high-value preventive medication on outcomes and costs. Given the frequency of knowledge and motivation-related barriers, we will also assess the impact of a tailored self-management education and facilitated relay strategy which, if effective, could be rolled out in a cost-efficient manner to primary care clinics that have rosters of patients with chronic diseases. By comprehensively measuring the impact of the interventions on both health outcomes and costs, as well as the impact on reducing health inequities in this vulnerable population, our study will facilitate informed formulary policy decisions.

Many interventions that seek to change patient behavior have not been successful at improving adherence or improving outcomes [61, 62], so our team decided to take a different approach by incorporating input from both patients and commercial marketing/design firms in the intervention development phase. We believe that this novel academic, industry, and patient co-design approach will provide a framework for future initiatives.

By comprehensively measuring the impact of the interventions on both health outcomes and costs, as well as the impact on reducing health inequities in this vulnerable population, policy-maker partners will have all the information required to make informed formulary policy decisions.

We will present our findings at national and international conferences on health policy and drug financing. We aim to publish our findings in academic general medical journals. Authorship will be determined by the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.

References

  1. World Health Organization. Cardiovascular diseases. http://www.who.int/cardiovascular_diseases/en/. Accessed 5 Jul 2016.

  2. Statistics Canada. Mortality, summary list of causes. Ottawa: Statistics Canada; 2011.

    Google Scholar 

  3. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med. 1985;21:1063–9.

    Article  CAS  PubMed  Google Scholar 

  4. Keeler EB, Brook RH, Goldberg GA, Kamberg CJ, Newhouse JP. How free care reduced hypertension in the health insurance experiment. JAMA. 1985;254:1926–31.

    Article  CAS  PubMed  Google Scholar 

  5. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421–9.

    Article  CAS  PubMed  Google Scholar 

  6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–44.

    Article  CAS  PubMed  Google Scholar 

  7. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617–22.

    Article  CAS  PubMed  Google Scholar 

  8. Nelson KM, McFarland L, Reiber G. Factors influencing disease self-management among veterans with diabetes and poor glycemic control. J Gen Intern Med. 2007;22:442–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, et al. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. PLoS One. 2014;9:e90434.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Campbell D, King-Shier K, Hemmelgarn B, Sanmartin C, Ronksley P, Weaver R, et al. Assessing the association of financial barriers on care and outcomes for patients with chronic disease. Health Rep. 2014;25.

  11. Alberta Blue Cross. Plans for individuals and families. https://www.ab.bluecross.ca/individuals-families/index.html Accessed. 5 Jul 2016.

  12. Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy. 2012;104:19–26.

    Article  PubMed  Google Scholar 

  13. Interdisciplinary chronic disease collaboration. Barriers to Care for People with Chronic Health Conditions Survey. http://www.icdc.ca/research/selected-projects#5-barriers-to-care-for-people-with-chronic-health-conditions-bcpchc-survey Accessed. 5 Jul 2016.

  14. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002;288:2469–75.

    Article  PubMed  Google Scholar 

  15. Ansari Z, Laditka JN, Laditka SB. Access to health care and hospitalization for ambulatory care sensitive conditions. Med Care Res Rev. 2006;63:719–41.

    Article  PubMed  Google Scholar 

  16. Canadian Institute for Health Information (CIHI). Technical note: ambulatory care sensitive conditions (ACSC). www.cihi.ca/CIHI-ext-portal/pdf/internet/DEFINITIONS_052010_EN Accessed. 5 Jul 2016.

  17. Friedman B, Basu J. The rate and cost of hospital readmissions for preventable conditions. Med Care Res Rev. 2004;61:225–40.

    Article  PubMed  Google Scholar 

  18. Booth G, Hux J. Relationship between avoidable hospitalizations for diabetes mellitus and income level. Arch Intern Med. 2003;163:101–6.

    Article  PubMed  Google Scholar 

  19. Campbell D, Ronksley P, Barnabe C, Tonelli M, Hemmelgarn B, Manns B. The association of enrolment in primary care networks on diabetes care and outcomes in low income and first nations Albertans. Open Med. 2012;6:E155–65.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tang KL, Bamieh L, Mann B, Clement F, Campbell DJT, Hemmelgarn BR, et al. A systematic review of value-based insurance design in chronic diseases. Am J Manag Care. 2014;20:E229–40.

    PubMed  Google Scholar 

  21. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97.

    Article  CAS  PubMed  Google Scholar 

  22. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379:2252–61.

    Article  PubMed  Google Scholar 

  23. Serrano V, Rodriguez-Gutierrez R, Hargraves I, Gionfriddo MR, Tamhane S, Montori VM. Shared decision-making in the care of individuals with diabetes. Diabet Med. 2016;33:742–51.

    Article  CAS  PubMed  Google Scholar 

  24. Statistics Canada. Table 051-0001 Population by year, by province and territory. Ottawa: Statistics Canada; 2015.

    Google Scholar 

  25. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–45.

    Article  CAS  PubMed  Google Scholar 

  26. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–97.

    Article  PubMed  PubMed Central  Google Scholar 

  27. O’Connor PJ. Patient archetypes, physician archetypes, and tailored diabetes care. J Am Board Fam Pract. 2002;15:334–7.

    PubMed  Google Scholar 

  28. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8:e80633.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Pedersini R, Vietri J. Comparison of the 4-item and 8-item morisky medication adherence scale in patients with type 2 diabetes. Value Health. 2014;17:A196.

    Article  Google Scholar 

  30. Afshar AE, Weaver RG, Lin M, Allan M, Ronksley PE, Sanmartin C, et al. Capacity and willingness of patients with chronic noncommunicable diseases to use information technology to help manage their condition: a cross-sectional study. CMAJ Open. 2014;2:E51–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Manns BJ, Tonelli M, Zhang J, Campbell DJ, Sargious P, Ayyalasomayajula B, et al. Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes. CMAJ. 2012;184:E144–52.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, et al. Overview of the Alberta kidney disease network. BMC Nephrol. 2009;10:30.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Manns B, Tonelli M, Culleton B, Faris P, McLaughlin K, Chin R, et al. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephro. 2012;7:565–72.

    Article  CAS  Google Scholar 

  34. Hemmelgarn B, Manns B, Lloyd A, James MT, Klarenbach S, Quinn R, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423–9.

    Article  CAS  PubMed  Google Scholar 

  35. Hemmelgarn BR, James MT, Manns BJ, O’Hare AM, Muntner P, Ravani P, et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA. 2012;307:2507–15.

    Article  CAS  PubMed  Google Scholar 

  36. Hemmelgarn BR, Zhang JG, Manns BJ, James MT, Quinn RR, Ravani P, et al. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA. 2010;303:1151–8.

    Article  CAS  PubMed  Google Scholar 

  37. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14.

    Article  PubMed  Google Scholar 

  38. Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, et al. Access to health care among status aboriginal people with chronic kidney disease. CMAJ. 2008;179:1007–12.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25:512–6.

    Article  PubMed  Google Scholar 

  40. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54:1423–8.

    Article  CAS  PubMed  Google Scholar 

  41. Canadian Institute for Health Information (CIHI). Technical Note: ambulatory care sensitive conditions. http://www.cihi.ca/CIHI-ext-portal/internet/en/document/health+system+performance/indicators/health/tech_acsc_2011 Accessed. 5 July 2016.

  42. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182–8.

    Article  PubMed  Google Scholar 

  43. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144:290–6.

    Article  PubMed  Google Scholar 

  44. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005;36:1776–81.

    Article  PubMed  Google Scholar 

  45. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived rom ICD-9-CCM administrative data. Med Care. 2002;40:675–85.

    Article  PubMed  Google Scholar 

  46. Robitaille C, Bancej C, Dai S, Tu K, Rasali D, Blais C, et al. Surveillance of ischemic heart disease should include physician billing claims: population-based evidence from administrative health data across seven Canadian provinces. BMC Cardiovasc Disord. 2013;13:88.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9.

    Article  PubMed  Google Scholar 

  48. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457–64.

    PubMed  PubMed Central  Google Scholar 

  49. Pharmacy Quality Alliance. Adherence. http://pqaalliance.org/resources/adherence.asp Accessed. 5 July 2016.

  50. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303–10.

    Article  PubMed  Google Scholar 

  51. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabet Med. 2011;28:395–413.

    Article  CAS  PubMed  Google Scholar 

  52. Sach TH, Barton GR, Doherty M, Muir KR, Jenkinson C, Avery AJ. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond). 2007;31:189–96.

    Article  CAS  Google Scholar 

  53. Culleton BF, Walsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291–9.

    Article  CAS  PubMed  Google Scholar 

  54. Euroqoul. EQ-5D-5 L. http://www.euroqol.org/eq-5d-products/eq-5d-5l.html Accessed. 5 July 2016.

  55. Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One. 2012;7:e31115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Fernandez S, Chaplin W, Schoenthaler AM, Ogedegbe G. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med. 2008;31:453–62.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24.

    Article  Google Scholar 

  58. Vuong QH. Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica. 1989;57:307–33.

    Article  Google Scholar 

  59. McBrien KA, Manns BJ, Chui B, Klarenbach SW, Rabi D, Ravani P, et al. Health care costs in people with diabetes and their association with glycemic control and kidney function. Diabetes Care. 2013;36:1172–80.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H, et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol. 2013.

  61. Rash JA, Cambell DJT, Tonelli M, Campbell T. A systematic review of interventions to improve adherence to statin medication: what do we know about what works? Prev Med. In press

  62. Pladevall M, Divine G, Wells KE, Resnicow K, Williams LK. A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educ. 2015;41:136–46.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The study is funded by Alberta Innovates-Health Solutions, the University of Calgary Clinical Research Fund, and the Canadian Institutes of Health Research (through an investigator Foundation grant (Manns)). The funding partners and trial sponsor had no input into the study design or data collection methods. They will not have access to trial data or any input into analysis or interpretation of results, or writing of the report, including decision to submit for publication.

Alberta Innovates-Health Solutions, University of Calgary Clinical Research Fund Canadian Institutes of Health Research Foundation Grant (Manns).

Composition, roles and responsibilities of study committees: Study Coordinating Centre: Terry Saunders-Smith, Sharon Gulewich, Nicole MacDonald, Alexa Desjarlais.

Steering Committee: Braden Manns, Brenda Hemmelgarn, Marcello Tonelli, David Campbell, Chad Mitchell, Ross Tsuyuki.

Endpoint Adjudication Committee: Derek Exner, Peter Faris.

Data Management Team: Peter Faris, Jianguo Zhang, Terry Saunders-Smith, Sharon Gulewich.

Availability of data and materials

The full study protocol will be made available on our website (ICDC.ca) and statistical code will be made available at the time of publication; however, the participant-level dataset will not be made publicly available due to restrictions set by our data access agreement.

Authors’ contributions

DC is a co-investigator and primary proposal author, and will conduct study analyses, along with PF. MT, BH, RT, NI, TC, SK, KK-S, PF, DE, and VC helped design the study, and provided key revisions to the study protocol. CM was a liaison with the Alberta government, ensuring key input on the value-based formulary, and providing key revisions to the study protocol. PF designed the statistical analysis, and provided key revisions to the study protocol. RP and EV helped design intervention 2, and provided key revisions to the study protocol. BM is the principal investigator, developed the study idea with DC and the other authors, acquired study funding along with BH, and MT, and wrote and revised sections of the final protocol presented herein. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

We have received approval from our institutional review board (University of Calgary Conjoint Health Research Ethics Board (CHREB) #: 13-1241; University of Alberta Health Research Ethics Board #PRO00062473). Protocol modifications will be decided upon by the steering committee and will need to be approved by CHREB prior to implementation. In cases where such modifications may affect a participant’s intervention or data, they will be notified in writing of the proposed changes prior to implementation.

Informed consent to participate in the ACCESS trial is received via a two-step process: initially, consent to participate in the telephone screening interview is obtained verbally. Once eligibility is confirmed, study information packages are sent (electronically or in the post) to potential participants to obtain written informed consent (Additional file 1: Appendix 4). Proxy consent is permitted for participants who do not speak English fluently and who have a close family member or friend who will agree to read consent forms to the participant in their native language. Explicit consent will be obtained for linkage to participants’ administrative health data records.

Confidentiality will be assured through the use of a unique dual data capture system. Identifiable information (name, date of birth, personal health number) will only be stored on the secured, encrypted server. By contrast, all surveys and data collection instruments are sent from an anonymized twinned version of this dataset. Unique study identification numbers will be used to permit linkage from the anonymized to the secure side of the database.

Author information

Authors and Affiliations

  1. Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada

    David J. T. Campbell

  2. Departments of Medicine and Community Health Sciences, Libin Institute and Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Canada

    Marcello Tonelli, Brenda Hemmelgarn, Derek Exner & Braden Manns

  3. Alberta Health, Edmonton, Canada

    Chad Mitchell

  4. Department of Pharmaceutical Sciences, University of Alberta, Edmonton, Canada

    Ross Tsuyuki

  5. Department of Family Medicine, University of Toronto, Toronto, Canada

    Noah Ivers

  6. Department of Psychology, University of Calgary, Calgary, Canada

    Tavis Campbell

  7. Emergence Creative, New york, USA

    Raj Pannu & Eric Verkerke

  8. Department of Medicine, University of Alberta, Edmonton, Canada

    Scott Klarenbach

  9. Faculty of Nursing, University of Calgary, Calgary, Canada

    Kathryn King-Shier

  10. Alberta Health Services, Edmonton, Canada

    Peter Faris

  11. Department of Medicine, University of British Columbia, Vancouver, Canada

    Vikas Chaubey

  12. Foothills Medical Centre, 1403 29th St. NW, Calgary, Alberta, Canada, T2N 2T9

    Braden Manns

Authors
  1. David J. T. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcello Tonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brenda Hemmelgarn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chad Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ross Tsuyuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noah Ivers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tavis Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Raj Pannu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eric Verkerke
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Scott Klarenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kathryn King-Shier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Peter Faris
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Derek Exner
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Vikas Chaubey
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Braden Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Interdisciplinary Chronic Disease Collaboration

Corresponding author

Correspondence to Braden Manns.

Additional file

Additional file 1: Appendix 1.

Medications included in copayment elimination intervention. Appendix 2. ICD10-CA definitions of the components of our primary clinical endpoint. Appendix 3. Alberta Kidney Disease Network Administrative Database. Appendix 4. Informed consent form. (DOCX 131 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campbell, D.J.T., Tonelli, M., Hemmelgarn, B. et al. Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)—study protocol for a 2×2 factorial randomized trial. Implementation Sci 11, 131 (2015). https://doi.org/10.1186/s13012-016-0491-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13012-016-0491-6

Keywords

Implementation Science

ISSN: 1748-5908